Strategic Growth Avalon is expanding with next-generation diagnostics technology and has attracted strategic investments from Francisco Partners and WindRose, signaling readiness for rapid product development and broader payer/provider adoption. This creates cross-sell opportunities with larger health plans and integrated delivery networks seeking advanced diagnostic intelligence.

Payer Collaboration Existing support for over 30 health plans and 90 million members indicates a strong position to upsell expanded Diagnostic Insights Platform capabilities, add-on modules for routine and genetic testing management, and automated adherence across more payer contracts.

Awards and Talent Recent recognition as a USA TODAY Top Workplace and Tampa Bay Top Workplace reinforces Avalon’s value proposition to attract and retain experienced sales and customer success talent, enabling stronger enterprise relationships and longer-term contracts with health systems and payers.

Financial Health With revenue in the range of 100M-250M and a recent funding round totaling 54M, Avalon has capital to invest in platform enhancements, go-to-market expansion, and partnerships that accelerate adoption of diagnostic intelligence across the care continuum.

Tech-Enabled Advantage The proprietary Diagnostic Insights Platform combined with a modern tech stack and data analytics capabilities position Avalon as a differentiator for health plans and providers seeking evidence-based, real-time diagnostics policies and optimized lab networks, enabling cross-sell into lab network management and decision-support services.